{
    "clinical_study": {
        "@rank": "151552", 
        "arm_group": [
            {
                "arm_group_label": "Praziquantel (PZQ)", 
                "arm_group_type": "Active Comparator", 
                "description": "A single dose of praziquantel (40 mg/kg) was administered orally on day-1 only, and after 7 days, 1 g of corn oil/soybean oil (50%/50%), for 15 consecutive days of school."
            }, 
            {
                "arm_group_label": "Arachidonic acid (ARA)", 
                "arm_group_type": "Experimental", 
                "description": "A single daily dose of 1 g microbial arachidonic acid-rich oil administered orally for 15 consecutive days of school."
            }, 
            {
                "arm_group_label": "PZQ + ARA", 
                "arm_group_type": "Experimental", 
                "description": "A single dose of PZQ (40 mg/kg) was administered orally on day-1 only, and after 7 days, followed the next day by 1 g of microbial ARA-rich oil, administered orally as a single dose on 15 consecutive days of school."
            }
        ], 
        "brief_summary": {
            "textblock": "Randomized Controlled Trial:\n\n      The investigational materials used in this trial were administered to subjects each day by\n      trained clinicians.\n\n      Primary Objectives:\n\n        -  assess the effect of dietary supplementation with arachidonic acid on the cure rates\n           for Schistosomiasis mansoni with and without concomitant treatment with praziquantel.\n\n        -  assess the safety of dietary supplementation using arachidonic acid in  children with\n           clinically confirmed schistosomiasis mansoni infection.\n\n      Secondary objective:\n\n        -  to measure changes in total phospholipids in plasma."
        }, 
        "brief_title": "Arachidonic Acid Treatment Against Schistosomiasis Infection in Children", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": [
            "Schistosomiasis", 
            "Bilharzia"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Schistosomiasis", 
                "Schistosomiasis mansoni"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  consent from parent or legal guardian\n\n          -  clinically confirmed schistosomiasis\n\n        Exclusion Criteria:\n\n          -  not infected with schistosomiasis\n\n          -  less than 6 or greater than 15 years of age"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "6 Years"
        }, 
        "enrollment": {
            "#text": "335", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02144389", 
            "org_study_id": "2012-1054"
        }, 
        "intervention": [
            {
                "arm_group_label": "Praziquantel (PZQ)", 
                "description": "40 mg/kg, a single dose, administered orally\n1 g of corn/soybean oil (50%/50%), administered orally", 
                "intervention_name": "Praziquantel (PZQ)", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Praziquantel (generic)", 
                    "Biltricide", 
                    "trematodicide"
                ]
            }, 
            {
                "arm_group_label": "Arachidonic acid (ARA)", 
                "description": "ARA (40% of total fatty acid)", 
                "intervention_name": "Arachidonic acid (ARA)", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "ARASCO", 
                    "Microbial arachidonic acid-rich oil"
                ]
            }, 
            {
                "arm_group_label": "PZQ + ARA", 
                "description": "A single dose of PZQ administered seven days in advance of initial treatment with ARA.", 
                "intervention_name": "PZQ+ARA", 
                "intervention_type": "Dietary Supplement", 
                "other_name": [
                    "ARASCO", 
                    "praziquantel"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Praziquantel"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Arachidonic acid", 
            "Bilharzia", 
            "Mansoni", 
            "Schistosomiasis", 
            "Polyunsaturated fatty acid"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Shebin El-Kom", 
                        "country": "Egypt", 
                        "state": "Menoufiya"
                    }, 
                    "name": "National Liver Institute, Menoufiya University,"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Alexandria", 
                        "country": "Egypt"
                    }, 
                    "name": "Tropical Health Department, High Institute of Public Health, Alexandria University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cairo", 
                        "country": "Egypt"
                    }, 
                    "name": "Cairo University"
                }
            }
        ], 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effects of Arachidonic Acid Supplementation on Schistosomiasis Mansoni Infection in Egyptian School Children", 
        "overall_official": [
            {
                "affiliation": "Cairo University", 
                "last_name": "Rashika El Ridi", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Liver Institute, Menoufiya University", 
                "last_name": "Sahar Selim, Ph.D.", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "High Institute of Public Health, Alexandria University", 
                "last_name": "Rashida Barakat, Ph.D.", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Health and Population", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Stool samples were collected from each child on three consecutive days to determine egg counts per gram of stool.", 
            "measure": "Percent egg reduction", 
            "safety_issue": "No", 
            "time_frame": "4 weeks after end of 1 day PZQ treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02144389"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood samples were collected using 4 vacutainer tubes. Serum was used to measure enzyme markers of liver and kidney functions. Coagulation tests included prothrombin- and activated thromboplastin times were measured using citrated blood. Complete hematological profiles were obtained using EDTA-anticoagulated blood samples.", 
                "measure": "Biochemical and hematological parameters", 
                "safety_issue": "Yes", 
                "time_frame": "Three days after a 15-day ARA supplementation"
            }, 
            {
                "description": "Blood samples (10 ml) were collected 2-3 days before the start of treatment, and 3 days after completion of treatment with ARA or PZQ+ARA for analysis of the phospholipids in plasma.", 
                "measure": "Total plasma phospholipids", 
                "safety_issue": "No", 
                "time_frame": "Three days after 15-day ARA supplementation."
            }
        ], 
        "source": "DSM Nutritional Products, Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "National Liver Institute, Egypt", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Cairo University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "High Institute of Public Health, Egypt", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "DSM Nutritional Products, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}